Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.65 |
| ▸ | CA1 | P00915 | 8/20 | 0.65 |
| ▸ | CA2 | P00918 | 8/20 | 0.65 |
| ▸ | CA5A | P35218 | 8/20 | 0.65 |
| ▸ | CA9 | Q16790 | 8/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 8/20 | 0.65 |
| ▸ | SLC12A5 | Q9H2X9 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25892474 | 0.92 | CA12 (0.55) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL25892626 | 0.90 | CA12 (0.53) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL24767415 | 0.88 | CA12 (0.61) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL20888475 | 0.87 | CA12 (0.64) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL25893787 | 0.87 | CA12 (0.59) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL25894205 | 0.85 | CA12 (0.58) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL24767096 | 0.81 | CA12 (0.74) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL22427646 | 0.81 | CA12 (0.73) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL31187475 | 0.80 | CA12 (0.72) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL20876170 | 0.80 | CA12 (0.72) | CA12CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135303-A1 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | INNOVATIVE MOLECULES GMBH (DE) | 2023-07-20 | — | — | WO | disclosed |
| EP-4209491-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | Innovative Molecules GmbH (DE) | 2023-07-12 | — | — | EP | disclosed |
| EP-3692039-B1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| CN-109071473-B | Antiviral compounds | 创新分子股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| EP-3440063-B1 | AMINOTHIAZOLE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | INNOVATIVE MOLECULES GMBH (DE) | 2020-08-05 | — | — | EP | disclosed |
| EP-3440063-B1 | AMINOTHIAZOLE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | INNOVATIVE MOLECULES GMBH (DE) | 2020-08-05 | — | — | EP | disclosed |
| WO-2020109389-A1 | HELICASE PRIMASE INHIBITORS FOR TREATING CANCER IN A COMBINATION THERAPY WITH ONCOLYTIC VIRUSES | INNOVATIVE MOLECULES GMBH (DE) | 2020-06-04 | — | — | WO | disclosed |
| US-20200148652-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH (DE) | 2020-05-14 | — | — | US | disclosed |
| US-20200148652-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH (DE) | 2020-05-14 | — | — | US | disclosed |
| US-10590094-B2 | Aminothiazole derivatives useful as antiviral agents | INNOVATIVE MOLECULES GMBH (DE) | 2020-03-17 | — | — | US | disclosed |
| US-20190112285-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| CN-109071473-A | Novel antivirus compound | 创新分子股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148652-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | MAVS, EIF2AK2, SARS1 | CA12 4742/4885CA1 4843/4885CA2 4245/4885 |
| US-20190112285-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | MAVS, EIF2AK2, SARS1 | CA12 4770/4885CA1 4844/4885CA2 4253/4885 |
| US-10590094-B2 | Aminothiazole derivatives useful as antiviral agents | MAVS, EIF2AK2, SARS1 | CA12 4770/4885CA1 4844/4885CA2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.